| Literature DB >> 28003206 |
Sarah J Zyba1, Swapna V Shenvi1, David W Killilea1, Tai C Holland1, Elijah Kim1, Adrian Moy1, Barbara Sutherland1, Virginia Gildengorin1, Mark K Shigenaga1, Janet C King2.
Abstract
BACKGROUND: Food fortification has been recommended to improve a population's micronutrient status. Biofortification techniques modestly elevate the zinc content of cereals, but few studies have reported a positive impact on functional indicators of zinc status.Entities:
Keywords: DNA repair; antioxidant; inflammation; zinc biomarkers; zinc fortification
Mesh:
Substances:
Year: 2016 PMID: 28003206 PMCID: PMC5267297 DOI: 10.3945/ajcn.116.135327
Source DB: PubMed Journal: Am J Clin Nutr ISSN: 0002-9165 Impact factor: 7.045
Participant characteristics
| Value | |
| Ethnicity, % | |
| Caucasian | 33 |
| Asian | 28 |
| Indian | 17 |
| Other | 22 |
| Age, y | 23 ± 4 (20–37) |
| Height, m | 1.75 ± 0.05 (1.69–1.85) |
| Weight, kg | 67.8 ± 5.4 (58.7–77.6) |
| BMI, kg/m2 | 22 ± 2 (19–25) |
| Body composition, | |
| Lean mass | 84 ± 4 (76–92) |
| Fat mass | 16 ± 4 (8–24) |
| Prestudy dietary zinc, | 13.4 ± 6.6 (5.7–28.1) |
| Plasma zinc, | 75.0 ± 10.2 (61.4–102.5) |
| Hemoglobin, | 15.6 ± 0.7 (14.6–16.8) |
Mean ± SD; range in parentheses (all such values).
Measured with the use of a BOD POD whole-body air-displacement plethysmography device (COSMED USA).
Data from 10 men.
Baseline plasma zinc was measured with the use of inductively coupled plasma optical emission spectrophotometry.
Baseline hemoglobin was measured with the use of an automated complete blood count instrument (ADVIA 120 Hematology System; Siemens Healthcare GmbH).
Study dietary zinc and phytate amounts and measures of plasma zinc, EZP size, and fractional and total zinc absorption
| Metabolic period | Low zinc, MP1 | Moderate zinc, MP2 | |
| Dietary zinc, | 6.37 ± 1.54 | 10.37 | — |
| Phytate, g/d | 2.2 | 0.7 | — |
| Phytate:zinc molar ratio | 35.1 | 7.1 | — |
| Plasma zinc, μg/dL | 74.0 ± 10.1 | 78.8 ± 14.5 | NS |
| EZP, | 136 ± 43 | 154 ± 28 | 0.058 |
| EZP, mg/kg FFM | 2.64 ± 0.67 | 2.31 ± 0.73 | NS |
| FZA, % | 34.6 ± 13.8 | 28.2 ± 11.5 | 0.005 |
| Total absorbed zinc, | 2.1 ± 0.9 | 2.8 ± 1.2 | 0.005 |
EZP, exchangeable zinc pool; FFM, fat-free mass; FZA, fractional zinc absorption; MP1, metabolic period 1; MP2, metabolic period 2.
Paired t tests were used to calculate the significance between MP1 and MP2.
Dietary zinc was increased in MP2 by adding 1.33 mg Zn from zinc sulfate to each of the 2 meals for a total of an additional 4 mg Zn/d.
Mean ± SD (all such values).
Mean (all such values).
Stable-isotope studies for measuring the EZP at the end of the low-zinc period were measured with the use of 70Zn during the first week of MP2, and the EZP for the end of the moderate zinc period was measured the week after the completion of MP2. n = 15.
Total absorbed zinc equals the FZA (percentage) × dietary zinc (milligrams per day). The FZA for MP1 and MP2 was measured on day 4 of each period. n = 18.
Cellular measures of zinc status
| Indicator | Baseline | Low zinc, MP1 | Moderate zinc, MP2 |
| Erythrocyte zinc, fg/106 cells | 20.84 ± 2.46 | 20.18 ± 2.06 | 20.13 ± 2.10 |
| Leukocyte zinc, fg/cell | 10.22 ± 2.95 | 10.38 ± 2.55 | 10.83 ± 2.40 |
| Gene expression, fold change from baseline | |||
| Zip1 | 1.0 | 0.92 ± 0.54 | 1.12 ± 0.55 |
| Zip4 | 1.0 | 0.98 ± 0.29 | 1.11 ± 0.57 |
| Zip8 | 1.0 | 0.84 ± 0.39 | 0.85 ± 0.37 |
| ZnT1 | 1.0 | 1.39 ± 0.47 | 1.27 ± 0.62 |
| ZnT7 | 1.0 | 1.42 ± 0.71 | 1.35 ± 0.58 |
| Mt2a | 1.0 | 1.15 ± 0.58 | 1.24 ± 1.29 |
There were no significant differences in any cellular measures of zinc status. Baseline values were measured on day 1, MP1 values were measured on day 15, and MP2 values were measured on day 43. MP1, metabolic period 1; MP2, metabolic period 2; Mt2a, metallothionein 2a.
Mean ± SD (all such values).
Relative messenger RNA concentrations of zinc transporters and Mt2a at the end of MP1 and MP2 are expressed as ratios to baseline values with all baseline data normalized to 1.0. All mRNA concentrations are expressed relative to housekeeping genes as described in Methods.
Mean (all such values).
FIGURE 1Mean ± SD DNA strand breaks and oxidized lesions measured with the use of the alkaline comet and FPG comet assays. Olive tail moments (arbitrary units) from the alkaline comet assay are depicted with black bars; tail moments from FPG comets are depicted with gray bars. n = 18 for alkaline comets, and n = 13 for FPG comets. Significant differences between means were determined with the use of a repeated-measures ANOVA followed by Bonferroni’s multiple-comparisons test. Bars with the same letter or symbol represent means that are not significantly different from each other. DNA strand breaks increased from baseline (14.5% ± 4.7%) to the end of the low-zinc period (23.0% ± 6.3%; P < 0.001) and decreased by the end of the higher-zinc period (12.2% ± 3.7%; P < 0.001). Olive tail moments that were due to oxidation increased significantly from baseline (11.88% ± 4.17%) to the end of the low-zinc period (17.26% ± 7.83%; P = 0.01). FPG, formamidopyrimidine DNA-glycosylase.
Plasma proteins responding to a moderate 4 mg increase in dietary zinc
| MP1-to-MP2 change | ||
| Category 1: DNA damage and repair, % | ||
| TNF receptor superfamily member 1B | −7.62 ± 1.41 | 0.0002 |
| Importin subunit α-1 | −6.09 ± 0.04 | 0.001 |
| E3 ubiquitin-protein ligase Mdm2 | −4.08 ± 0.02 | 0.003 |
| High mobility group protein B1 | 21.89 ± 2.82 | 0.001 |
| Ubiquitin-conjugating enzyme E2 N | 13.91 ± 1.34 | 0.01 |
| Category 2: oxidative stress, % | ||
| MHC class I polypeptide-related sequence B | −8.7 ± 0.14 | 0.0002 |
| Platelet-derived growth factor receptor β | 6.71 ± 2.19 | 0.01 |
| Lactoperoxidase | −8.01 ± 0.3 | 0.01 |
| Peroxiredoxin-1 | 17.33 ± 0.76 | 0.001 |
| 6-phosphogluconate dehydrogenase, decarboxylating | 19.51 ± 1.99 | 0.001 |
| Ferritin | 24.95 ± 0.52 | 0.005 |
| Catalase | 13.95 ± 7.14 | 0.01 |
| Prostaglandin G/H synthase 2 | 6.18 ± 0.11 | 0.01 |
| Aflatoxin B1 aldehyde reductase member 2 | 13.52 ± 0.29 | 0.01 |
| Category 3: inflammation, % | ||
| TNF receptor superfamily member 1B | −7.62 ± 1.41 | 0.0002 |
| Fibrinogen | −5.54 ± 2.03 | 0.003 |
| Inter-α-trypsin inhibitor heavy chain H4 | −6.33 ± 4.09 | 0.003 |
| Resistin | −5.98 ± 0.18 | 0.004 |
| C-C motif chemokine 4-like | −8.73 ± 0.1 | 0.01 |
| TNF ligand superfamily member 6, soluble form | −6.05 ± 0.12 | 0.01 |
| α-1-Antichymotrypsin | −7.7 ± 5.84 | 0.01 |
| Fibronectin fragment 4 | 6.32 ± 1.57 | 0.01 |
| Apolipoprotein A-I | 10 ± 1.87 | 0.0004 |
| High mobility group protein B1 | 21.89 ± 2.82 | 0.001 |
| Ribosomal protein S6 kinase α-5 | 9.13 ± 0.04 | 0.003 |
| IL-2 receptor subunit α | 3.07 ± 0.07 | 0.005 |
All values are means + SEMs. n = 18. Paired t tests were used to determine significance. P < 0.01 was used as an arbitrary cutoff for significance. MHC, major histocompatibility complex; MP1, metabolic period 1; MP2, metabolic period 2.